re: one of these It's a strange one this.
The current sp is justified just from the sales growth alone. But when you throw in the potential if the product was marketed properly and the new indictions, with other chemo drugs, other cancers & primary cancers - the sp looks very silly indeed.
Surely now is the time for a bidder to step forward, imho.
genentech inc., page-10
Add SRX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $80.64M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | 21.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.0¢ | 1 | 1 |
View Market Depth
| Last trade - 16.12pm 19/07/2024 (20 minute delay) ? |
| SRX (ASX) Chart |
Day chart unavailable